1 day-12.13%
1 week-16.00%
1 month-75.32%
3 months-76.92%
6 months-72.00%
Current year-18.29%
1 week 0.41
Extreme 0.41
0.53
1 month 0.4
Extreme 0.4
1.72
Current year 0.4
Extreme 0.4
3.27
1 year 0.4
Extreme 0.4
3.27
3 years 0.2
Extreme 0.203
5.52
5 years 0.2
Extreme 0.203
19.4
10 years 0.2
Extreme 0.203
31.5
Manager TitleAgeSince
Chief Operating Officer 67 01/01/2006
Chief Executive Officer 73 -
Chief Executive Officer 50 29/12/2023
Director TitleAgeSince
Chairman 73 16/12/2024
Director/Board Member 67 01/01/2006
Chairman - -
Change 5-day change 1-year change 3-year change Capi.($)
-12.13%-16.00% - - 1.4M
+1.03%+9.74%+299.55%+42.93% 3.98B
-1.18%-3.61%+86.48%+256.53% 3.87B
-4.79%-1.87%+34.93%+59.29% 3.42B
+2.05%+2.19%+288.40%+422.92% 2.63B
-1.65%-6.73%-26.25%-32.04% 2.11B
-3.49%+10.28%+54.60% - 1.75B
-0.68%-4.69%+210.17%-28.93% 1.09B
+1.11%-10.52%+24.12%+41.15% 1.08B
-1.55%-11.92%+9.29%+49.84% 609M
Average -2.13%-0.67%+109.03%+101.46% 2.28B
Weighted average by Cap. -1.05%+0.77%+131.78%+130.71%
Logo 2cureX AB
2cureX AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of diagnostic substances to select treatment for cancer patients. The Company's product candidate, IndiTreat - CRC, aims at optimizing medical treatment for the colorectal cancer patients. Through IndiTreat - CRC, healthcare professionals collect a tumor sample from patients to create a number of three-dimensional micro tumors in order to test available chemotherapies and experimental treatments. The Company's product pipeline includes also IndiTreat - OVA, targeting ovarian cancer treatment, and IndiTreat - KDN, focusing on kidney cancer treatment. It operates through 2cureX A/S.
Employees
14
Date Price Change Volume
31/08/26 SEK 0.4200 -12.13% 380,699
28/08/26 SEK 0.4780 -4.40% 385,858
27/08/26 SEK 0.5000 -1.96% 649,154
  1. Stock Market
  2. Stocks
  3. 2CUREX Stock